ForsLean® is Sabinsa’s new proprietary composition extract of Coleus forskohlii root,
standardized for 10 percent forskohlin. ForsLean® has shown promising results in three areas;
enhancing lean body mass, promoting fat loss and promoting weight loss. In September of 1998
Sabinsa was granted a use patent for this application of forskohlin in its ForsLean® composition.
The importance of maintaining or regaining lean body mass has recently come to light for two important reasons. First is the increased recognition that lean body mass plays a vital role in any successful weight training regimen, and second, there is a growing awareness that lean body mass is proportionate to the overall health of an individual.
Lean body mass is composed of muscle, vital organs, bone and bone marrow, connective tissue and body water. The percentage of lean body mass to fat not only determines the body's aesthetic appearance, but more importantly, it is also an index of physical fitness, health status, susceptibility to disease and premature mortality. Because the body's metabolic rate is directly proportional to the amount of lean body mass, there is substantial interest in products that safely increase lean body mass because they are most likely to work. The use of ForsLean® may help to increase lean body mass and optimize body composition with one of the side effects being fat loss and/or weight loss.
A sluggish metabolic rate is an undesired effect of many weight-loss regimens. It was observed in one study that formerly obese subjects had a 3-5% lower resting metabolic rate than control subjects. The occurrence of a low resting metabolic rate is likely to contribute to the high rate of weight regain in formerly obese persons.
Clearly, we need to change and broaden our thinking on the objectives of weight management regimens for both active and not-so-active individuals. In particular,
it should be emphasized that healthy functioning of the body depends not so much on a lower fat content, but rather on obtaining a higher
percentage of lean body mass. Again, it should be kept in mind that it is not only fat, but also lean body mass that is, or can be,
lost through dieting. This fact often escapes our attention when we reduce our total body weight. The loss of lean body mass offsets any
benefits derived from the reduction of body weight, and can potentially increase one’s chances for diabetes, cardiovascular disease and
possibly some forms of cancer due to poor metabolic activity.
ForsLean® shifts the proportion between lean body mass and adipose, or fatty, tissue in favor of lean body mass, which improves overall health. The effect can be measured by decreases in the waist hip ratio and the body mass index.
The mechanism of action on how ForsLean® works is well defined. Forskohlin, the active compound in ForsLean®, is recognized as an adenylate
cyclase activator. Adenylate cyclase is the enzyme involved in the production of cyclic adenosine monophosphate (cAMP),
a significant biochemical agent in metabolic processes. The role of cyclic AMP is indispensable to many body functions.
It induces a chain reaction of biochemical events that trigger metabolic processes and diet induced thermogenesis, thereby
providing the means to maintain healthy body composition and lean body mass levels.
ForsLean® was tested in an open-field study with a population of six overweight women (BMI>25).
The tested formula was in the form of two-piece, hard shell capsules; each capsule contained 250 mg of ForsLean®.
. The overweight, but otherwise healthy women, received one capsule twice daily for eight weeks. Participants were
instructed to take one capsule in the morning and one in the evening, half an hour before a meal. Each participant
was asked to maintain her previous daily physical exercise and eating habits. In addition, physical activity was
monitored based on a questionnaire before and during the trial.
During the eight week trial, the mean values for body weight and fat content significantly decreased,
whereas lean body mass was significantly increased as compared to the baseline. Neither the systolic/diastolic
blood pressure, nor the pulse rate was adversely affect during the trial. Indeed, a trend was observed of lower
systolic/diastolic pressure during the course of treatment. A line graph is attached that shows actual results from this study.
ForsLean® has been clinically evaluated at one dose, 250 mgs twice daily. This provides 50 mgs of forskohlin, the primary active compound in ForsLean®.
Dosage has been in the form of a two-piece, hard shell capsule.
Sabinsa also offers standardized Coleus forskohlii extracts in concentrations of 1%, 20%, 40% 95% and 98% Forskohlin,
along with soft extracts in 10% and 20% that are suitable for soft-gel applications.
As mentioned in the beginning, with Sabinsa’s discovery of the lean body mass/weight loss properties of forskohlin, which was not a traditional use of the herb, the US Patent and Trademark Office granted to Sabinsa a use patent for this compound. This is not an achievement to be lightly passed over.
ForsLean® is a registered trademark of Sabinsa Corporation. US Patent #5,804,596
Sabinsa Wins Again: Federal Court Denies Creative Compounds Motion
Listen to a brief video on ForsLean®
View past and recent advertisements
Innovative Ingredients Paper Weight loss approach
Sabinsa calls to readers' attention that some of the products, protocols and uses of the products described here in are or may be subject to various restrictions or limitations because of patents, exclusive or nonexclusive licenses, confidentiality agreements and other intellectual property or equivalent rights. Readers are advised to make an early and thorough investigation and inquiry into any product, protocol or use in which they may be interested, to see if any such rights might be applicable. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.